Travere Therapeutics (TVTX) Other Non-Current Assets (2013 - 2026)

Travere Therapeutics has reported Other Non-Current Assets for 14 years, with the latest figure at $8.5 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets fell 54.65% year-over-year to $8.5 million; the trailing twelve-month figure through Mar 2026 stood at $8.5 million (down 54.65% YoY), and the FY2025 full-year result was $8.9 million, down 51.11% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $8.5 million, down from $8.9 million in the prior quarter.
• The five-year high for Other Non-Current Assets was $48.3 million in Q4 2022, with the low at $8.5 million in Q1 2026.
• Historically, Other Non-Current Assets has averaged $15.8 million across 5 years, with a median of $11.4 million in 2022.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets surged 336.73% — and 2023, when it plunged 77.95%.
• Travere Therapeutics' Other Non-Current Assets stood at $48.3 million in 2022, then sank by 77.95% to $10.7 million in 2023, then soared by 70.36% to $18.2 million in 2024, then sank by 51.11% to $8.9 million in 2025, then dropped by 4.55% to $8.5 million in 2026.
• The last three Other Non-Current Assets figures came in at $8.5 million (Q1 2026), $8.9 million (Q4 2025), and $10.3 million (Q3 2025), per Business Quant data.